Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
6
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
roche
6
×
deals
fda
san francisco blog main
clinical trials
genentech
san francisco top stories
avapritinib
blueprint medicines
cancer
eli lilly
europe blog main
europe top stories
investing
medullary thyroid cancer
non-small cell lung cancer
novartis
pralsetinib
selpercatinib
thyroid cancer
alexion pharmaceuticals
alnylam pharmaceuticals
biofourmis
biopharma
biovotion
boehringer ingelheim
cancer drugs
cancer immunotherapy
capmatinib
center for medicare and medicaid services
chugai pharmaceutical
companion diagnostic
cstone pharmaceuticals
What
roche
approval
drug
fda
medicines
billion
blueprint
cancer
gene
medicine
pay
recently
ret
team
therapeutics
therapy
acquire
address
agreed
analytics
approves
betting
big
biofourmis
biopharma
broad
candidate
carries
caught
causing
certain
confidence
currently
data
deal
designed
devices
dicerna
didn’t
digital
Language
unset
Current search:
boston
×
roche
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine